The use of TZM in combination with chemotherapy (CT) in the treatment of early-stage HER2+ BC improves survival by up to 35% (with 1 year of TZM use) and reduces the risk of recurrence by 33–52%, including loco-regional recurrence [1,4,5,7,8]. This evidence concerns the gene ERBB2 and breast cancer.